Eardley I, Broome G D, Murray A, Ramsay J W, Whitfield H N, Wilkinson D J
Department of Urology, St Bartholomew's Hospital, London.
Ann R Coll Surg Engl. 1989 Sep;71(5):278-80.
It has been reported that transurethral absorption of lignocaine may cause systemic toxicity when associated with mucosal damage within the urethra. We measured the serum levels of lignocaine in 30 patients after the transurethral administration of 400 mg lignocaine gel just before transurethral prostatectomy. In 11 patients additional lignocaine was given as part of the anaesthetic induction (Group A). In 19 patients no additional lignocaine was given (Group B). Two patients in Group A and three patients in Group B also underwent Otis urethrotomy. The mean peak plasma lignocaine concentration as measured by sequential venous samples was 1424 ng/ml in Group A and 72 ng/ml in Group B. We conclude that 400 mg lignocaine gel applied endourethrally before transurethral resection of the prostate results in plasma concentrations well below the toxic levels.
据报道，利多卡因经尿道吸收且伴有尿道黏膜损伤时可能会引起全身毒性。我们在30例患者经尿道前列腺切除术前经尿道给予400mg利多卡因凝胶后，测量了他们血清中的利多卡因水平。11例患者在麻醉诱导时额外给予了利多卡因（A组）。19例患者未额外给予利多卡因（B组）。A组2例患者和B组3例患者还接受了奥蒂斯尿道切开术。通过连续静脉采样测量，A组利多卡因血浆平均峰值浓度为1424ng/ml，B组为72ng/ml。我们得出结论，经尿道前列腺切除术前经尿道应用400mg利多卡因凝胶导致的血浆浓度远低于中毒水平。
